Discussion
cardiocerebrovascular diseases
ACUTE ISCHEMIC STROKE
In this randomized, double-blind, placebo-controlled, parallel-group clinical trial, GDLM dispensed within 48 hours after symptoms for patients with AIS improved the proportion of patients achieving a 90-day favorable functional outcome, which was defined as an mRS score of 0 or 1, compared with placebo.Neuroprotective agents, which could target cerebral parenchyma in the acute ischemic phase and restore neuronal function in the after-stroke phase, have been widely acknowledged as a promising option for AIS treatment.Recently, the exploratory analysis of the ESCAPE-NA1 (Efficacy and Safety of Nerinetide for the Treatment of Acute Ischemic Stroke) trial indicated a potential efficacy of nerinetide for patients who didn’t receive treatment of alteplase.Ginkgolide-related intravenous preparation is a class of multitargeted neuroprotectants widely used for the treatment of cardiocerebrovascular diseases in China,Ginkgo diterpene lactone meglumine has shown a multipathway neuroprotective and reparative effect in preclinical animal trials. For instance, it was reported to exert its neuroprotective effect through antioxidation, increasing the level of antioxidant enzymes, maintaining the dynamic balance of oxygen free radical formation, and restraining the trigger of lipid peroxidation.